Autolus Therapeutics plc reported its financial results for the third quarter of 2025, highlighting a significant increase in revenue driven by the launch of its product AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The company generated $21.1 million in product revenue for the three months ended September 30, 2025, compared to no revenue in the same period last year, marking a 100% increase. Total revenue for the quarter reached $21.2 million, a substantial rise from $0 in the prior year.
Despite the revenue growth, Autolus reported a net loss of $79.1 million for the third quarter, slightly lower than the $82.1 million loss recorded in the same quarter of 2024. For the nine months ended September 30, 2025, the net loss was $197.2 million, compared to $193.1 million for the same period in 2024. The company’s accumulated deficit increased to $1.296 billion as of September 30, 2025, up from $1.099 billion at the end of 2024. The increase in losses was attributed to higher costs associated with the commercialization of AUCATZYL and ongoing research and development expenses.
Operationally, Autolus has made significant strides in expanding its market presence. As of November 12, 2025, the company had activated 60 cancer treatment centers in the United States, achieving its target for the year. Additionally, patient access to AUCATZYL has improved, with coverage secured for over 90% of total medical lives in the U.S. The company is also in discussions with the National Institute for Health and Care Excellence (NICE) in the UK to secure reimbursement for AUCATZYL, with a commercial launch anticipated pending favorable outcomes.
In terms of financial health, Autolus reported cash and cash equivalents of $86.1 million and marketable securities of $281.3 million as of September 30, 2025. The company believes these resources will be sufficient to fund operations for at least the next twelve months. However, it cautioned that ongoing operating losses and the need for additional capital could impact its ability to execute its business strategy. The company plans to continue its focus on the commercialization of AUCATZYL while advancing its pipeline of product candidates through clinical development.
About Autolus Therapeutics plc
Autolus Therapeutics plc is a biopharmaceutical company specializing in next-generation programmed T cell therapies for cancer and autoimmune diseases. Its core product, AUCATZYL (obe-cel), is an autologous CD19-targeting CAR T cell therapy approved for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus develops modular, engineered T cell therapies designed to improve efficacy, safety, and durability, supported by proprietary manufacturing and global commercial capabilities targeting hematological and solid tumor markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.